Toxic epidermal necrolysis associated with combination therapy of spironolactone and torsemide
Authors/Creators
- 1. Patient safety pharmacovigilance Associate, Govt. TD Medical College, Vandanam, Alappuzha, Kerala, 688005, India
- 2. Govt. TD Medical College, Vandanam, Alappuzha, Kerala, 688005, India
- 3. Senior Principal Scientific officer, Indian Pharmacopoeia Commission, Ghaziabad, U.P.
Description
Abstarct
Dytor plus tablet is a fixed-dose combination of torsemide and spironolactone used for generalized edema. TEN is a serious, potentially life-threatening dermatological disorder. Here we present a case report of a 47-year-old female who was on Dytor Plus (5/50 mg)therapy once daily for generalized edema; presented to dermatology outpatient department with chief complaints of multiple erosions over oral cavity, swelling of lips with scaling, redness and burning sensation in both eyes, multiple well defined mostly erythematous rashes over the entire body since 2 days .on examination, her vital signs were stable and lab result indicate she had elevated SGOT(140 IU/L), SGPT (228 IU/L), ALP (162IU/L) and blood urea(47 mg/ml) values. The patient was diagnosed to have developed Dytor plus induced toxic epidermal necrolysis. Discontinued the medicine and prescribed with Dexamethasone injection, IgG Injection, Cefotaxime injection, Cloxacilline capsule, Cetirizine tablet, Hydroxypropyl methylcellulose eye drop, and candid mouth paint. The patient had a hospital stay of 25 days. The patient improved symptomatically. Causality was assessed as per the WHO-UMC causality scale and this case was put in the probable category. This case was uploaded via vigiflow under the pharmacovigilance programme of India having report Id 2019-30695.
Files
20201105 Melcy.pdf
Files
(194.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:49e993fb1a523a4d7ff0ad1e96c0aedc
|
194.4 kB | Preview Download |
Additional details
References
- David R. Byrd MD, Iftikhar Ahmed MD, Photosensitive Lichenoid Reaction to Torsemide-a Loop Diuretic, Mayo Clin Proc., 1997; 72: 930-931.
- Dunn CJ, Fitton A, Brogden RN Torasemide. Drugs, 1995; 49: 121–142.
- Goodman & Gilman's, Manual of pharmacology and therapeutics, New York, Mc Graw Hill, 2008.
- Greenblatt DJ, Koch-Weser J. Adverse Reactions to Spironolactone: A Report From the Boston Collaborative Drug Surveillance Program. JAMA. 1973; 225(1): 40-43.
- Joseph T. Dipiro, Encyclopedia of clinical pharmacy, Taylor & Francis, New York, 2003.
- Kim GK, Del Rosso JQ. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012; 5(3): 37-50.
- Mehta B, Iyer N, Iyer CM. Spironolactone‐ induced hypersensitivity in a patient with acne vulgaris. Indian J Drugs Dermatol, 2016; 2(1): 40‐1.
- Robert A, Mihaela D, Florentina F, Daniel B. An Inventory Of Medicinal Products Causing Skin Rash: Clinical And Regulatory Lessons Experimental And Therapeutic Medicine, 2019; 18: 5061-5071.
- Sundar S, Dickinson PD. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Rep. 2012; 2012: bcr1120115238. Published 2012 Feb 25
- Vikas S, Ramesh M, Rani VN, Thennarasu P and Kannan G: Incidence of diuretics induced adverse drug reactions in an intensive cardiac care unit of a tertiary care teaching hospital. Int J Pharm Sci Res., 2017; 8(8): 3557-62
- Wang Y and Lipner SR, Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration, International Journal of Women's Dermatology, 2020.